Skip to main content
. 2018 Feb 22;7(3):690–697. doi: 10.1002/cam4.1356

Figure 2.

Figure 2

Overall survival of patients in our dataset treated with nivolumab + ipilimumab combination based upon the number of unfavorable variables for nivolumab + ipilimumab defined in this manuscript. As the number of unfavorable factors for combination immunotherapy outcomes increases, the OS of patients treated with the combination in our dataset generally decreases.